Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BioRestorative Therapies, Inc. - Common Stock (NQ:BRTX)

0.2327 +0.0027 (+1.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BioRestorative Therapies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results ↗
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony... 
Via Benzinga
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
By Faith Ashmore, Benzinga 
Via TheNewswire.com
Topics Intellectual Property
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies 
Via News Direct
News headline image
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) may have had a successful year of novel drug development. 
Via Benzinga
News headline image
BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication
From BioRestorative Therapies, Inc
Via GlobeNewswire
News headline image
EXCLUSIVE: BioRestorative Secures Funding Support For Programs Against Polycystic Ovary Syndrome ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has received a Small Business Innovation Research (SBIR) Phase I grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development... 
Via Benzinga
News headline image
BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease
From BioRestorative Therapies, Inc
Via GlobeNewswire
News headline image
EXCLUSIVE: BioRestorative Therapies Gets Exclusive License Rights From Regenexx For Development Of BRTX-100 Disc Program To Treat Chronic Lumbar Disc Disease ↗
BioRestorative Therapies, Inc (NASDAQ: BRTX), a stem cell-based therapies clinical-stage company, forged an agreement with Regenexx, LLC, under which BRTX gets exclusive license rights for intellectual... 
Via Benzinga
BioMedNewsBreaks – BioRestorative Therapies Inc. (NASDAQ: BRTX) to Participate at RHK Capital Disruptive Growth Conference
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
BioRestorative Therapies to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022
From BioRestorative Therapies, Inc
Via GlobeNewswire
Chronic Obstructive Pulmonary Disease (COPD) Market Expected to Reach $25 Billion By 2027
EQNX::TICKER_START (OTCQB:OCEL),(NASDAQ:BRTX),(NASDAQ:MDXG),(NYSE:NNVC),(NASDAQ:VCEL) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
By Faith Ashmore, Benzinga 
Via News Direct
The NIH Has Given BioRestorative Therapies A Stamp Of Approval
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes. 
Via TheNewswire.com
News headline image
The NIH Has Given BioRestorative Therapies A Stamp Of Approval ↗
BioRestorative Therapies Inc. (NASDAQ: BRTX) is working on products that may be solutions to conditions that affect millions of Americans with lower back pain and diabetes.  
Via Benzinga
News headline image
See What's Next For The Regenerative Medicine Field -- BioRestorative Intends to Lead The Pack In Stem Cell Therapies! ↗
While stem cell therapy has always been a more controversial topic, as the general public has gained more knowledge on the practice and induced pluripotent stem (iPS) cells have gained traction in... 
Via Benzinga
News headline image
BioRestorative Therapies CEO Lance Alstodt to be Interviewed on Famela and Friends Talk Radio Show
From BioRestorative Therapies, Inc
Via GlobeNewswire
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via TheNewswire.com
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field
By David Willey, Benzinga 
Via News Direct
News headline image
A Look At Some Of The Companies Innovating In the Cutting-Edge Regenerative Medicine Field ↗
Biotechnology companies have broken many medical barriers in the past 40 years, harnessing the technological revolution to bring innovative solutions to medical problems. 
Via Benzinga
News headline image
Why Senti Biosciences Shares Jumped Over 50%; Here Are 79 Biggest Movers From Yesterday ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares climbed 50.7% to close at $2.11 on Thursday after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
News headline image
Why Sunlight Financial Shares Are Trading Lower By 59%, Here Are 54 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Senti Biosciences, Inc. (NASDAQ: SNTI) shares jumped 52% to $2.1325 after B of A Securities initiated coverage on the stock with a Buy rating and $7 price target. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2022 ↗
Upgrades 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
Gainers Acumen Pharmaceuticals (NASDAQ:ABOS) shares increased by 80.8% to $8.5 during Wednesday's pre-market session. The company's market cap stands at $344.2 million. 
Via Benzinga
News headline image
BioRestorative Therapies to Present at the Dawson James Securities 7th Annual Small Cap Growth Conference
From BioRestorative Therapies, Inc
Via GlobeNewswire
News headline image
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
By Paul Henley, Benzinga 
Via News Direct
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. That’s why BioRestorative... 
Via TheNewswire.com
Obesity And Back Pain: BioRestorative Therapies Inc. Is Working To Address 2 Common Ailments That Plague Americans with a Major Near Term Data Catalyst ↗
In 2016, Americans spent roughly $380 billion on lower back and neck pain. In the same year, medical costs for adult obesity in the United States were $260.6 billion. 
Via Benzinga
News headline image
EXCLUSIVE: BioRestorative Therapies Adds Additional Sites For Lumbar Disc Disease Trial ↗
BioRestorative Therapies Inc (NASDAQ: BRTX) has entered into agreements with Vantage Clinical Trials LLC for its Phase 2 trial targeting chronic lumbar disc disease (cLDD).  
Via Benzinga
News headline image
Giving Metabolism A Boost? BioRestorative Uses Science Surrounding Brown Fat Cells To Provide A Possible Breakthrough In Metabolic Disorders ↗
In 2017, 41.9% of Americans experienced some level of obesity. Adults experiencing obesity in 2019 spent an average of $1,861 more on medical expenses than people with a healthy weight. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.